Kohei Takahashi1, Osamu Nakagawasai2, Wataru Nemoto1, Takeharu Nakajima1, Yuichiro Arai3, Tadashi Hisamitsu4, Koichi Tan-No1. 1. Department of Pharmacology, Tohoku Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai, 981-8558, Japan. 2. Department of Pharmacology, Tohoku Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai, 981-8558, Japan. osamun@tohoku-pharm.ac.jp. 3. Department of Health Science, Ariake University of Medical and Health Science, 2-9-1 Ariake, Koto-Ku, Tokyo, 135-0063, Japan. 4. Department of Physiology, School of Medicine, Showa University, 1-5-8 Hatanodai, Shinagawa-Ku, Tokyo, 142-8666, Japan.
Abstract
BACKGROUND: Olfactory bulbectomy (OBX) in rodents is considered a putative animal model of depression. It has been reported that some abnormal behaviors observed in this animal model of depression involve dopaminergic neurons of the mesolimbic pathway. Therefore, we examined changes in the dopaminergic system in the caudate putamen (CPu), nucleus accumbens core (NAcC), and shell (NAcSh) of OBX mice and whether or not these alterations were reversed by chronic administration of imipramine. METHODS: We observed climbing behavior, which is a dopamine (DA) receptor-associated behavior, to demonstrate changes in the dopaminergic system of the mesolimbic pathway, when mice were administrated either the nonselective DA agonist apomorphine only or were pre-treated with the selective D1 antagonist SCH23390, with the selective D2 antagonist sulpiride, or with the D2/D3 partial agonist aripiprazole (ARI). Moreover, we examined tyrosine hydroxylase (TH) and D1- and D2-like receptor levels in the CPu, NAcC, and NAcSh using immunohistochemistry and autoradiography. RESULTS: The OBX group exhibited significantly enhanced apomorphine-induced climbing behavior, and this enhanced behavior was reversed by administration of sulpiride, ARI, and imipramine but not SCH23390. Moreover, we found a reduction in TH levels in the CPu, NAcC, and NAcSh of OBX mice and an increase in D2 receptor densities in the NAcC of OBX mice. The increased D2 receptor density observed in OBX mice was reversed by imipramine administration. CONCLUSIONS: These findings reveal that OBX mice display enhanced DA receptor responsiveness, which may relate to some of the behavioral abnormalities reported in this animal model.
BACKGROUND: Olfactory bulbectomy (OBX) in rodents is considered a putative animal model of depression. It has been reported that some abnormal behaviors observed in this animal model of depression involve dopaminergic neurons of the mesolimbic pathway. Therefore, we examined changes in the dopaminergic system in the caudate putamen (CPu), nucleus accumbens core (NAcC), and shell (NAcSh) of OBX mice and whether or not these alterations were reversed by chronic administration of imipramine. METHODS: We observed climbing behavior, which is a dopamine (DA) receptor-associated behavior, to demonstrate changes in the dopaminergic system of the mesolimbic pathway, when mice were administrated either the nonselective DA agonist apomorphine only or were pre-treated with the selective D1 antagonist SCH23390, with the selective D2 antagonist sulpiride, or with the D2/D3 partial agonist aripiprazole (ARI). Moreover, we examined tyrosine hydroxylase (TH) and D1- and D2-like receptor levels in the CPu, NAcC, and NAcSh using immunohistochemistry and autoradiography. RESULTS: The OBX group exhibited significantly enhanced apomorphine-induced climbing behavior, and this enhanced behavior was reversed by administration of sulpiride, ARI, and imipramine but not SCH23390. Moreover, we found a reduction in TH levels in the CPu, NAcC, and NAcSh of OBX mice and an increase in D2 receptor densities in the NAcC of OBX mice. The increased D2 receptor density observed in OBX mice was reversed by imipramine administration. CONCLUSIONS: These findings reveal that OBX mice display enhanced DA receptor responsiveness, which may relate to some of the behavioral abnormalities reported in this animal model.
Authors: Nigel S Bamford; Siobhan Robinson; Richard D Palmiter; John A Joyce; Cynthia Moore; Charles K Meshul Journal: J Neurosci Date: 2004-10-27 Impact factor: 6.167
Authors: Philip V Holmes; Cher V Masini; Stefany D Primeaux; Joshua L Garrett; Andrew Zellner; Kimberly S Stogner; Alicia A Duncan; Jonathon D Crystal Journal: Synapse Date: 2002-10 Impact factor: 2.562
Authors: Heloísa Helena de Alcantara Barcellos; Fabiana Kalichak; João Gabriel Santos da Rosa; Thiago Acosta Oliveira; Gessi Koakoski; Renan Idalencio; Murilo Sander de Abreu; Ana Cristina Varrone Giacomini; Michele Fagundes; Cristiane Variani; Mainara Rossini; Angelo L Piato; Leonardo José Gil Barcellos Journal: Sci Rep Date: 2016-11-22 Impact factor: 4.379
Authors: Marina F de Souza; José M M Bispo; Pollyana C Leal; Auderlan M de Gois; José R Dos Santos Journal: Front Behav Neurosci Date: 2017-05-19 Impact factor: 3.558
Authors: Alesha Heath; Daniel R Lindberg; Kalina Makowiecki; Avalon Gray; Anders J Asp; Jennifer Rodger; Doo-Sup Choi; Paul E Croarkin Journal: Transl Psychiatry Date: 2018-07-05 Impact factor: 6.222